For the quarter ending 2025-09-30, BDTX had $874K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -8,498 | 45,981 |
| Stock-based compensation expense | 1,739 | 3,477 |
| Depreciation expense | 86 | 173 |
| (accretion) amortization on investments | 292 | 838 |
| Gain on sale of investments | 0 | 3 |
| Noncash rent expense | 791 | 1,549 |
| (gain) loss on sale of equipment | 1 | 23 |
| Prepaid expenses and other current assets | -475 | 573 |
| Other non-current assets | -44 | -88 |
| Accounts payable | 204 | -3,236 |
| Accrued expenses and other current liabilities | -1,464 | -532 |
| Non-current operating lease liabilities | -934 | -1,812 |
| Net cash provided by (used in) operating activities | -7,850 | 44,251 |
| Proceeds from sale of equipment | 1 | 23 |
| Proceeds from sales and maturities of investments | 23,500 | 62,583 |
| Purchases of investments | 14,911 | 113,212 |
| Net cash provided by (used in) investing activities | 8,590 | -50,606 |
| Proceeds from exercise of common stock options and espp, net of restricted stock surrendered for taxes | 134 | -84 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 0 |
| Net cash provided by financing activities | 134 | -84 |
| Net (decrease) increase in cash and cash equivalents | 874 | -6,439 |
| Cash and cash equivalents at beginning of period | 37,256 | - |
| Cash and cash equivalents at end of period | 31,691 | - |
Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. (BDTX)